Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy.

ABSTRACT: Resistance to human epidermal growth factor receptor 2 (HER2)-targeted therapies in the treatment of HER2-positive breast cancer is a major clinical problem. To identify pathways linked to resistance, we generated HER2-positive breast cancer cell lines which are resistant to either lapatinib or AZD8931, two pan-HER family kinase inhibitors. Resistance was HER2 independent and was associated with epithelial-to-mesenchymal transition (EMT), resulting in increased proliferation and migration of the resistant cells. Using a global proteomics approach, we identified a novel set of EMT-associated proteins linked to HER2-independent resistance. We demonstrate that a subset of these EMT-associated genes is predictive of prognosis within the ERBB2 subtype of human breast cancers. Furthermore, targe

SUBMITTER: Creedon H 

PROVIDER: S-EPMC4905492 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature